3B Blackbio DX Ltd

3BBLACKBIO

Watchlist

AI Mode

‌

Market Cap

₹ 1,217 Cr

P/E

24.79

Turned 1 L into 4.54 L in last 5 Years

‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

REASONABLE

Growth

EXCEPTIONAL

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

3B BlackBio Dx Limited, originally Kilpest India Limited, is a prominent Indian biotech company focusing on molecular diagnostics and agrochemicals.

In FY 2025, the company acquired Coris BioConcept SRL, enhancing its molecular diagnostics capabilities and expanding its product reach globally, especially in the AMR sector.

The company exhibits strong R&D capabilities, offering a comprehensive range of molecular diagnostic tests, including pioneering assays such as TRUPCR and TRUNGS, across a broad international market.

With a 12%-15% market share in India’s molecular diagnostics sector, 3B BlackBio plans a 15%-20% growth by leveraging its expansive product line and increasing market penetration.

Their CSR efforts emphasize healthcare accessibility, disability support, and educational programs, reflecting their commitment to societal well-being.

Sector

Healthcare

Industry

Medical Accessories / Disposables

Market Cap

1,217 Cr

Volatility

Moderate Risk

P/E Ratio

24.8

Industry P/E

33.0

PEG Ratio

0.3

P/B Ratio

4.1

52W High

2,205.00

52W Low

1,151.00

Sales CAGR

30.15%

80.00%

46.29%

10Y

20.26%

Profit CAGR

48.57%

81.10%

138.69%

10Y

85.05%

ROE

TTM

16.47%

15.27%

24.86%

10Y

24.29%

ROCE

TTM

21.74%

20.36%

32.87%

10Y

31.96%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
3BBLACKBIO	1420.00	1,217 Cr	24.79	4.08	0.28	16.47	21.74	14.44
PREVEST	476.00	576 Cr	29.38	4.99	0.21	16.98	22.79	15.94
MHHL	39.85	73 Cr	7.21	0.69	1.25	3.22	5.30	-1.67
KMSMEDI	126.50	42 Cr	95.11	5.16	0.04	7.12	10.19	4.85
CSURGSU	97.30	36 Cr	—	1.23	0.00	-6.78	1.96	-2.50
GML	23.00	35 Cr	10.60	0.96	0.00	9.32	12.62	8.10
BANDARAM	30.48	34 Cr	159.61	2.69	0.35	1.73	4.13	0.55

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	14	19	18	23	19	29	25	23	22	34
Expenses	7.85	11	8.80	13	8.49	13	10	15	10	19
Operating Profit	6.43	7.79	8.87	9.88	11	16	15	7.92	12	15
OPM %	45.03	40.62	50.20	42.96	56.30	55.51	59.35	35.20	53.22	43.45
Other Income	2.96	2.75	2.63	4.19	3.69	3.44	3.01	4.94	4.32	5.51
Interest	0.02	0.04	0.03	0.04	0.01	0.03	0.02	0.04	0.01	0.04
Depreciation	0.19	0.24	0.32	0.30	0.27	0.27	0.27	0.28	0.28	0.58
Profit Before Tax	9.19	10	11	14	14	19	18	13	16	20
Tax %	21.55	26.02	23.68	35.98	21.31	22.99	24.16	35.89	20.30	23.34
Net Profit	7.21	7.59	8.52	8.79	11	15	14	8.04	13	15
EPS in Rs	7.36	7.75	8.70	10.26	13.19	17.35	15.75	9.38	14.76	17.55

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	17	23	23	29	227	81	62	74	96	99
Expenses	14	18	16	20	77	44	33	41	46	48
Operating Profit	3.78	5.64	7.22	9.32	150	37	29	33	50	51
OPM %	21.73	24.07	31.02	32.27	66.15	46.00	47.08	44.49	51.94	51.38
Other Income	0.27	0.28	0.74	1.60	2.89	6.90	7.26	13	15	16
Interest	0.98	0.73	0.46	0.33	0.23	0.11	0.20	0.12	0.11	0.10
Depreciation	0.45	0.46	0.55	0.54	0.62	0.67	0.86	1.06	1.09	1.10
Profit Before Tax	1.40	4.52	6.95	10	152	43	35	44	64	66
Tax %	18.99	24.13	24.60	23.52	25.10	25.50	26.54	27.59	25.48	25.14
Net Profit	1.13	3.43	5.24	7.69	114	32	26	32	48	49
EPS in Rs	1.21	3.99	5.76	8.94	132.49	36.65	27.92	34.06	55.67	57.44
Dividend Payout %	17.44	9.31	6.10	6.82	5.92	24.43	8.26	8.01	7.19	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.38	6.38	6.38	6.39	7.49	7.49	7.49	8.57	8.57	8.57
Reserves	4.04	4.83	12	16	25	125	146	185	214	260
Borrowings	7.73	8.69	5.80	6.19	3.52	2.00	2.53	2.03	0.85	0.31
Other Liabilities	5.94	5.75	6.22	7.64	9.20	59	37	19	24	27
Total Liabilities	24	26	30	36	45	194	192	214	248	296
Fixed Assets	3.35	3.28	3.75	3.97	3.87	5.00	6.61	7.79	7.40	7.22
CWIP	0.12	0.05	0.15	0.10	0.20	0.13	0.11	0.09	0.00	0.00
Investments	0.00	0.00	0.00	0.00	1.20	59	93	92	117	156
Other Assets	21	22	27	32	40	130	93	114	123	132
Total Assets	24	26	30	36	45	194	192	214	248	296

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.94	0.67	1.94	3.57	7.04	98	37	20	27	43
Cash from Investing Activity	-0.02	-0.41	-1.02	-0.69	-0.64	-70	-28	15	-20	-34
Cash from Financing Activity	-0.85	-0.26	0.24	-1.09	0.81	-1.57	-15	-5.01	-3.63	-3.22
Net Cash Flow	0.07	0.00	1.16	1.79	7.21	26	-6.19	30	3.01	6.29

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Feb 2024	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	38.43%	38.43%	38.43%	38.43%	41.29%	41.29%	41.29%	41.29%	41.29%	41.28%	41.28%	41.28%
FIIs	2.54%	3.06%	3.16%	3.38%	2.97%	2.97%	3.28%	3.27%	2.68%	2.49%	0.00%	2.64%
DIIs	0.00%	0.00%	0.82%	1.18%	1.89%	1.89%	1.96%	1.96%	1.74%	1.60%	4.46%	1.82%
Public	59.03%	58.51%	57.59%	57.00%	53.85%	53.85%	53.48%	53.49%	54.29%	54.63%	54.26%	54.26%
Total Shareholders	13,136	12,416	10,513	10,088	9,753	9,753	9,399	9,586	10,166	10,345	10,619	10,709

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Mar 24, 2025	Mahesh kumar upadhyay revised	Insider - Promoter	Disposal	1,755.42	0.04 Cr	250	0.00
Mar 22, 2025	Mahesh kumar upadhyay	Insider - Promoter	Disposal	—	—	250	0.00
Jun 21, 2024	Abdul moin khan	Insider - Director	Disposal	1,225.00	0.06 Cr	500	0.00
Oct 13, 2023	Nikhil kuber dubey	Insider - Promoter & Director	Acquisition	10.00	0.08 Cr	83,300	1.10
Oct 13, 2023	Dhirendra dubey	Insider - Promoter & Director	Acquisition	10.00	0.33 Cr	3,33,200	4.44

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Analyst/Investor Meet

1 day ago

Schedule of Analyst/Investor Meeting

3B BlackBio Dx Limited has scheduled an Analyst/Investor Meeting on December 20, 2025, from 13:00 to 14:00 hrs India Time.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Investor Presentation

Q2 FY24

Showing 1 - 8 of 38

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

3B BlackBio Dx Limited, originally Kilpest India Limited, is a prominent Indian biotech company focusing on molecular diagnostics and agrochemicals.

In FY 2025, the company acquired Coris BioConcept SRL, enhancing its molecular diagnostics capabilities and expanding its product reach globally, especially in the AMR sector.

The company exhibits strong R&D capabilities, offering a comprehensive range of molecular diagnostic tests, including pioneering assays such as TRUPCR and TRUNGS, across a broad international market.

With a 12%-15% market share in India’s molecular diagnostics sector, 3B BlackBio plans a 15%-20% growth by leveraging its expansive product line and increasing market penetration.

Their CSR efforts emphasize healthcare accessibility, disability support, and educational programs, reflecting their commitment to societal well-being.

Sector

Healthcare

Industry

Medical Accessories / Disposables

Market Cap

1,217 Cr

Volatility

Moderate Risk

P/E Ratio

24.8

Industry P/E

33.0

PEG Ratio

0.3

P/B Ratio

4.1

52W High

2,205.00

52W Low

1,151.00

Sales CAGR

30.15%

80.00%

46.29%

10Y

20.26%

Profit CAGR

48.57%

81.10%

138.69%

10Y

85.05%

ROE

TTM

16.47%

15.27%

24.86%

10Y

24.29%

ROCE

TTM

21.74%

20.36%

32.87%

10Y

31.96%